Home›Stock Screener›SMS Pharmaceuticals

SMS Pharmaceuticals Share Price Today | Stock Price & SMS Pharmaceuticals Share Screener

SMSPHARMA Pharmaceuticals & Biotechnology
Live Share Price NSE
₹481.35
▲ 4.55 (0.95%)
2026-11-19 00:00:00
Live Share Price BSE
₹482.35
▲ 4.85 (1.02%)
2026-11-19 00:00:00

As of November 19, 2026, the live SMS Pharmaceuticals share price (NSE: SMSPHARMA) is ₹481.35 on NSE and ₹482.35 on BSE, up 0.95% from the previous close, with shares trading between ₹467.35 and ₹484.00 in today's trading session, and a 52-week range of ₹271.55–₹525.50. Track SMS Pharmaceuticals market worth to gauge the company's total market size. Use the SMS Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today SMS Pharmaceuticals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹317 and net income of ₹40, with EBITDA of ₹69, an operating margin of 21.0% and a profit margin of 12.6%.

SMS Pharmaceuticals Market Cap ₹4,556.17 Cr.
SMSPHARMA P/E Ratio (TTM) 40.70
SMS Pharmaceuticals P/B Ratio 5.65
EPS (TTM) ₹9.58
Dividend Yield 0.08%
Debt to Equity 0.47
SMSPHARMA 52 Week High ₹525.50
SMS Pharmaceuticals 52 Week Low ₹271.55
Operating Margin 21.00%
Profit Margin 12.62%
SMSPHARMA Revenue (TTM) ₹317.00
EBITDA ₹69.00
Net Income ₹40.00
Total Assets ₹1,362.00
Total Equity ₹786.00

SMS Pharmaceuticals Share Price Chart

Track the current stock price of SMS Pharmaceuticals with an interactive chart. Analyse SMSPHARMA share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete SMS Pharmaceuticals stock quote in one place.

The quote of ₹481.35 sits between the 52-week low of ₹271.55 and the 52-week high of ₹525.50, and the latest session moved 0.95% from the previous close.

SMS Pharmaceuticals Company Profile - Fundamental Screener

Screen SMS Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SMSPHARMA shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE812G01025.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE812G01025

SMS Pharmaceuticals Balance Sheet Screener

Screen SMSPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹1,362, up from ₹1,153 in 2025.

Latest statistics put total assets at ₹1,362 and shareholder funds at ₹786, with a leverage ratio of 0.47.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 1,362 1,153 1,034 880 860 812 608 559 503 493
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 534 533 437 412 438 457 281 281 279 291

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 224 189 166 164 193 206 115 94 97 91
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 786 640 536 461 470 411 348 322 285 255
Share Capital 9 9 9 9 9 9 9 9 9 9
Reserves & Surplus 776 615 499 452 462 402 340 314 276 246

SMS Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis

Screen SMS Pharmaceuticals income statement and profit fundamentals. Analyze SMSPHARMA quarterly results. SMS Pharmaceuticals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Sept, revenue was ₹317 and net profit was ₹40, equal to earnings per unit of ₹4.26, at an operating margin of 21%.

In that period expenses were ₹248, interest cost ₹6 and tax ₹13. The next period listed, 2026-Jun, shows revenue of ₹209 and net profit of ₹21.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec 2023-Sept 2023-Jun 2023-Mar

Revenue and Expenses

Revenue 317 209 241 214 244 197 250 176 198 166 248 163 167 136 151
Expenses 248 166 198 167 194 157 207 140 165 131 212 133 139 109 126

Operating Costs and Margins

EBITDA 69 43 43 47 50 40 42 35 33 35 35 31 29 27 25
Operating Profit % 21.00% 20.00% 17.00% 21.00% 20.00% 20.00% 16.00% 19.00% 16.00% 20.00% 14.00% 18.00% 17.00% 19.00% 16.00%
Depreciation 10 10 10 10 10 10 9 9 9 8 8 8 8 8 8
Interest 6 6 5 6 6 6 5 4 5 5 6 6 6 6 6

Profit and Earnings

Profit Before Tax 53 27 27 31 34 24 29 22 20 22 22 17 15 13 11
Tax 13 6 -6 8 9 4 8 4 5 5 5 5 3 3 4
Net Profit 40 21 33 24 25 21 20 18 14 17 17 12 12 9 6
EPS 4.26 2.23 3.58 2.59 2.84 2.31 2.40 2.15 1.67 1.95 2.04 1.36 1.39 1.10 0.73

SMS Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals

Screen SMSPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹59, and net cash flow was an inflow of ₹5.

Over the same period, investing activities used ₹131 and financing activities provided ₹76.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 59 82 50 23 45 90 40 50 32 74
Investing Activities -131 -123 -52 -30 -27 -152 -43 -35 -17 -39

Financing and Net Cash

Financing Activities 76 47 31 -32 -12 92 -2 -13 -15 -33
Net Cash Flow 5 5 29 -39 6 31 -5 2 0 1

SMS Pharmaceuticals Shareholding Pattern Screener

See SMS Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check SMS Pharmaceuticals promoter holding and ownership changes for SMSPHARMA on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 68.07%, foreign institutions 0.31%, domestic institutions 3.02% and the public 23.17%, spread across 32,397 shareholders.

The shareholder count was 32,397 in 2026-Mar, compared with 31,489 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 68.07% 68.07% 68.07% 66.26% 66.26% 68.07% 68.07% 64.67%

Institutional Investors

FII Holding 0.31% 0.65% 1.18% 0.08% 0.03% 0.28% 0.04% 0.17%
DII Holding 3.02% 2.83% 0.20% 2.43% 3.03% 2.88% 3.21% 1.98%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 23.17% 24.04% 25.86% 26.35% 25.89% 24.02% 24.08% 27.93%
Other Holding 5.43% 4.41% 4.71% 4.87% 4.78% 4.76% 4.61% 5.25%
Shareholder Count 32,397 31,489 34,904 35,332 33,652 33,009 34,378 30,140

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by SMS Pharmaceuticals. SMS Pharmaceuticals dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.40 per unit for 2026-March, a yield of 0.08%, compared with ₹0.40 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.40, ₹0.40 and ₹0.40 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.40 0.08%
2025-March ₹0.40 0.11%
2024-March ₹0.40 0.19%
2023-March ₹0.30 0.17%
2022-March ₹0.30 0.53%
2021-March ₹0.30 0.32%
2020-March ₹0.25 0.20%
2019-March ₹0.25 0.93%
2018-March ₹0.25 0.40%
2017-March ₹0.20 0.27%

SMS Pharmaceuticals Stock Index Membership - Nifty & Sensex

See which indices include SMS Pharmaceuticals stock. Check SMSPHARMA index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 2 indices, including BSE INDEX BSE HC.

Among the benchmarks tracked are BSE INDEX BSE HC, BSE INDEX SMLCAP.

Complete Index List

BSE INDEX BSE HC
BSE INDEX SMLCAP

SMS Pharmaceuticals Market Events Screener - Corporate Actions

Get SMS Pharmaceuticals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check SMS Pharmaceuticals stock events that may affect SMSPHARMA share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 4, 2026, with a record date of November 4, 2026.

It is followed by Annual General Meeting dated September 29, 2026 and Dividend dated September 22, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-04 2026-11-04 Quarterly Result Announcement NA 16.01%
2026-09-29 2026-09-29 Annual General Meeting NA 23.25%
2026-09-22 2026-09-22 Dividend ₹ 0.40 /share 9.55%
2026-07-31 2026-07-31 Quarterly Result Announcement NA -1.69%
2026-05-22 2026-05-22 Quarterly Result Announcement NA 6.36%
2026-02-07 2026-02-07 Quarterly Result Announcement NA 0.44%
2025-11-08 2025-11-08 Quarterly Result Announcement NA 0.91%
2025-09-29 2025-09-29 Annual General Meeting NA 12.38%
2025-09-22 2025-09-22 Dividend ₹ 0.40 /share 8.19%
2025-08-09 2025-08-09 Quarterly Result Announcement NA -2.17%
2025-05-30 2025-05-30 Quarterly Result Announcement NA 3.00%
2025-02-12 2025-02-12 Quarterly Result Announcement NA -2.50%
2024-11-08 2024-11-08 Quarterly Result Announcement NA 3.84%
2024-09-30 2024-09-30 Annual General Meeting NA 12.37%
2024-09-23 2024-09-23 Dividend ₹ 0.40 /share 75.63%

SMS Pharmaceuticals Competitors Screener - Peer Stocks Comparison

Screen SMSPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 448,076 41.10 61,674 12.69% 11,565 59.98
Divis Laboratories 294,139 90.70 11,067 13.95% 2,568 67.88
Torrent Pharmaceuticals 178,438 84.50 13,886 20.34% 2,138 49.31
Laurus Labs 119,949 98.10 6,868 22.01% 890 49.19
Zydus Life Science 118,902 27.60 27,658 17.64% 5,026 52.87
Dr Reddys Laboratories 115,011 41.70 35,059 3.90% 4,158 69.34
Cipla 112,656 39.40 29,045 2.24% 3,870 55.82
Mankind Pharma 108,490 48.40 14,636 14.85% 1,938 63.62
Aurobindo Pharma 103,223 26.40 34,145 5.56% 3,503 60.38
Lupin 90,393 17.30 29,039 26.75% 5,356 44.23

SMS Pharmaceuticals Company Announcements - News & Reports Screener

Screen SMSPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 14, 2026.

The next most recent announcements are dated November 5, 2026 and November 5, 2026.

Date Update Actions
2026-11-14 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-11-05 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-11-05 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-04 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-11-04 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-11-04 Financial Results And Change In Company Secretary -
2026-11-04 Announcement under Regulation 30 (LODR)-Change in Management -
2026-11-04 Board Meeting Outcome for Outcome Of Board Meeting And Financial Results -
2026-11-02 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-31 Receipt Of Order From Income Tax Department -
2026-10-31 Order Received From The Income Tax Department -
2026-10-30 Loan Agreement With The Subsidiary Of The Company -
2026-10-28 Board Meeting Intimation for Approval Of Financial Results For The Quarter Ended 30 September 2026 -
2026-10-07 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-09-30 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-29 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-24 Closure of Trading Window -
2026-09-10 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-09-05 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-04 Letter To Shareholders Regarding Annual Report -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹481.35, within a 52-week range of ₹271.55 to ₹525.50. The P/E ratio is 40.70 and the P/B ratio is 5.65, with earnings per unit of ₹9.58. Market capitalisation stands at ₹4,556.17 Cr and the dividend yield is 0.08%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.